RxDoctor Payments Data

Sidney Jones, MD

Endocrinology, Diabetes & Metabolism · Chaska, MNNPI 1508806811

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $58,791 of the $66,523 with a category attached, or 88.4%. AstraZeneca accounts for 67.6% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2019 at $39,946 and has fallen 99.7% since, to $120 in 2025. Among endocrinology, diabetes & metabolism clinicians in MN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$66,523in general payments, 2019–2025

Across 118 payments — averaging $563.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$45K
  • Sanofi-aventis U.S. LLC$9K
  • Lilly USA, LLC$8K
  • Boehringer Ingelheim$4K
  • Intuity Medical Inc$118
  • Sequel Med Tech, LLC$70
  • plus $258 from 9 others

What the payments were for

  • Consulting fees$3,6005%
  • Speaking & faculty fees$58,79188%
  • Travel & lodging$2,1663%
  • Food & beverage$1,8773%
  • Education$890%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$66,523 in reported general payments places this provider in the 90th percentile of 120 endocrinology, diabetes & metabolism providers in Minnesota.

See all endocrinology, diabetes & metabolism providers in Minnesota

Medicare billing

Part B allowed, 2024
$99,985
Medicare patients
344
Services billed
1,738

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide569$624,960
OzempicSemaglutide528$544,726
FarxigaDapagliflozin Propanediol236$271,397
JardianceEmpagliflozin228$243,173
TrulicityDulaglutide186$196,144
Lantus SolostarInsulin Glargine,hum.Rec.Anlog310$44,739
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog91$40,984
JanuviaSitagliptin Phosphate34$40,589
RybelsusSemaglutide29$39,748
Victoza 3-PakLiraglutide41$38,419
Humalog Kwikpen U-100Insulin Lispro135$36,797
Tresiba Flextouch U-200Insulin Degludec33$36,506
TradjentaLinagliptin37$30,536
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/735$27,061
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog39$26,286

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity, Humalog$8,407$827,899779 claims
Novo NordiskOzempic, Rybelsus, Novolog$66$589,918582 claims
Boehringer IngelheimJardiance, Tradjenta, Trijardy Xr$4,058$281,664276 claims
AstraZenecaFarxiga$44,945$271,397236 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$8,667$19,20421 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 120 endocrinology, diabetes & metabolism providers in Minnesota.

Other endocrinology, diabetes & metabolism in Chaska

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →